2021 American Transplant Congress
Letermovir Prophylaxis in Solid Organ Transplant – CMV Breakthrough and Tacrolimus Drug Interaction
*Purpose: Valganciclovir is the preferred drug for cytomegalovirus (CMV) prophylaxis in solid organ transplantation. A limitation to its use is profound myelosuppression. Letermovir is a…2021 American Transplant Congress
Outcomes After Abo Incompatible Pediatric Liver Transplantation are Comparable to Abo Identical/compatible Transplant
*Purpose: In order to evaluate if the incidence of vascular and biliary complications as well as patient and graft survival in ABO incompatible (ABOi) liver…2021 American Transplant Congress
Accounting for Survivor Bias in Transplant Benefit Models
*Purpose: The lung allocation system in the U.S. prioritizes lung transplant candidates based on estimated pre- and post-transplant survival. However, these models do not account…2021 American Transplant Congress
Paired Surveillance Biopsies Over >4 Years from a Multi-Center Cohort of 78 Long-Term Pediatric Liver Transplant Recipients
*Purpose: Progressive liver fibrosis threatens graft and patient longevity for children after liver transplantation (LT). Previous studies are limited to single-center, cross-sectional analyses. To address…2021 American Transplant Congress
A Pediatric Liver Allograft with an Occult Urea Cycle Defect Carrier Mutation Causing Delayed Graft Function and Metabolic Crisis After Liver Transplantation
Cincinnati Children's Hospital Medical Center, Cincinnati, OH
*Purpose: We report an interesting case of delayed graft function following pediatric liver transplantation, which was attributed to previously unrecognized urea cycle carrier genetic defect…2021 American Transplant Congress
Role of Recovering Surgeon in DCD Liver Transplant Outcomes
*Purpose: Donation after cardiac death (DCD) liver transplant (LT) outcomes have continued to improve. Variability in outcomes has been attributed to center and recovering surgeon…2021 American Transplant Congress
Waitlist Outcomes for Exception Candidates Following the Implementation of MMaT/250 Score
1Johns Hopkins Medical Institutions, Baltimore, MD, 2Temple University, Philadelphia, PA
*Purpose: Starting in May 2019, exception points were allocated based on DSA-level median-MELD-at-transplant (MMaT/DSA). In February 2020, the exception point system was further modified based…2021 American Transplant Congress
Evaluation of Increasing Liver Discard Rate and Waiting List Drop-Off in Post-MELD Era
*Purpose: As number of donors and transplant cases rises each year, it is important to evaluate not only post-transplant survival rate but also the organ…2021 American Transplant Congress
Clearance of Viral RNA and DNA and Antibody Response Following Administration of Live Attenuated Measles and Varicella Vaccines in Children with Chronic Liver Disease
1Children's Hospital Colorado, Denver, CO, 2University of Colorado Denver, Denver, CO
*Purpose: Guidelines recommend waiting four weeks between live vaccine administration and transplantation; however, there is little data to support this waiting period and it often…2021 American Transplant Congress
Immunologic Benefits of Maternal Living Donor Allografts in Pediatric Liver Transplantation: Less Rejection Episodes and No Evidence of De Novo Allosensitization
*Purpose: Living donor liver transplantation (LDLT) offers improved graft and patient survival in pediatric liver transplant (LT) recipients. Prior studies have suggested immunological advantage when…
- « Previous Page
- 1
- …
- 219
- 220
- 221
- 222
- 223
- …
- 1683
- Next Page »